Entities / Company
Eisai.
Japanese pharmaceutical company
- Reports this week
- 2
- Active events
- 0
- Connections
- 33
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
Eisai and an entity in Osaka Prefecture collaborate on initiatives focused on dementia awareness and support.Some support1 report
-
Biogen, Eisai, and Morgan Stanley announced strategic shifts regarding the LEQEMBI treatment pathway simplification.Some support1 report
-
Eisai is seeking reimbursement for its drug LEQEMBI to target Alzheimer's disease in the Canadian market.Some support1 report
One to three months ago
-
BioArctic and Eisai partnered to present clinical evidence regarding lecanemab.Some support3 reports1 development inside
-
BioArctic and Eisai developed the drug Leqembi.Some support1 report
-
Biogen, Eisai, and BioArctic announced the joint commercialization of lecanemab for Alzheimer's treatment.Well supported3 reports1 development inside
-
The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.Some support4 reports2 developments inside
-
FDA approved subcutaneous dose for lecanemab initiation.Some support1 report
-
Biogen and Eisai received FDA approval for a new drug formulation aimed at Alzheimer's disease.Well supported7 reports
-
Eisai presented study results from a study conducted in Stockholm at a conference held in London.Some support1 report
Gone quiet
No new reports in 90+ days-
Biogen and Eisai are involved in the LEQEMBI launch, with Biogen headquartered in Cambridge and Eisai in Tokyo.Some support3 reports2 developments inside
-
Eisai is headquartered in Tokyo.Some support4 reports
-
Santiago Arroyo was appointed as a Non-Executive Director, and his career history includes work at Pfizer, Bristol Myers Squibb, Eisai, and Schwarz Pharma.Some support1 report
-
Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.Some support3 reports
-
EMA initially rejected Kisunla due to ARIA risks, affecting companies involved in Alzheimer's drug development.Some support2 reports
-
Dr. Kirk Shepard joined BP Logix's Life Sciences Strategic Advisory Board, leveraging his extensive background in the pharmaceutical industry.Some support1 report
-
UCB, Eisai, Lundbeck, and GW Pharmaceuticals are identified as key players in a market supported by supportive FDA policies.Some support1 report
-
The pharmaceutical industry is seeing developments in ALS drug treatment, including partnerships and drug approvals involving major companies.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Eisai this week
News at the entities that move Eisai most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Eisai
-
Stockholm Shared contextHemnet, Sweden's largest property portal, is based in Stockholm.Moves Eisai
-
London Shared contextHelen Flanagan is leading a suspected state-threat investigation through Counter Terrorism Policing in London.Moves Eisai
-
Tokyo Shared contextEgypt is promoting tourism in Tokyo.Moves Eisai
Connections
The 7 strongest of 33, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Biogen Structural
Biogen and Eisai are formally partnered for the joint development, commercialization, and revenue sharing of the Alzheimer's drug Leqembi.
-
FDA Structural
FDA formally regulated and approved Eisai's Biologics License Application (BLA) for Leqembi Iqlik.
-
BioArctic Structural
BioArctic and Eisai are in a strategic research alliance for the co-development and commercialization of Leqembi, with BioArctic receiving royalties.
-
Osaka Prefecture Operational
Osaka Prefecture and Eisai collaborate on dementia awareness and support initiatives.
-
Tokyo Shared context
Eisai is headquartered in the city of Tokyo.
-
Stockholm Shared context
Eisai utilized Stockholm as the location for presenting research findings related to its studies.
-
London Shared context
Eisai presented study results at a conference held in London.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
2 eventsJuly 2026
2 eventsShow 1 earlier month
June 2026
12 events- BioArctic and Eisai partnered to present clinical evidence regarding lecanemab.
- Biogen, Eisai, and BioArctic announced the joint commercialization of lecanemab for Alzheimer's treatment.
- The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.
- Biogen and Eisai received FDA approval for a new drug formulation aimed at Alzheimer's disease.
- Biogen and Eisai are involved in the LEQEMBI launch, with Biogen headquartered in Cambridge and Eisai in Tokyo.
- Eisai is headquartered in Tokyo.
- Santiago Arroyo was appointed as a Non-Executive Director, and his career history includes work at Pfizer, Bristol Myers Squibb, Eisai, and Schwarz Pharma.
- Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.
- EMA initially rejected Kisunla due to ARIA risks, affecting companies involved in Alzheimer's drug development.
- Dr. Kirk Shepard joined BP Logix's Life Sciences Strategic Advisory Board, leveraging his extensive background in the pharmaceutical industry.
- UCB, Eisai, Lundbeck, and GW Pharmaceuticals are identified as key players in a market supported by supportive FDA policies.
- The pharmaceutical industry is seeing developments in ALS drug treatment, including partnerships and drug approvals involving major companies.